Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic
Abstract Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disease. Despite the availability of several therapies, many patients affected by this disease remain untreated, do not have adequate response, or suffer from treatment-related toxic effects. It has been shown that the i...
Main Authors: | Spyridon Gkalpakiotis, Martina Kojanová, Jorga Fialová, Petra Cetkovská, Vladimír Vašků, Yvetta Vantuchová, Alena Machovcová, Petra Gkalpakioti, Pavla Hrdá, Petr Arenberger |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-11-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s13555-023-01066-z |
Similar Items
-
Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
by: Roman M, et al.
Published: (2017-07-01) -
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024-02-01) -
Brodalumab
by: Murat Borlu
Published: (2022-04-01) -
Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
by: Hampton P, et al.
Published: (2021-11-01) -
Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
by: Kristian Reich, et al.
Published: (2022-03-01)